Bristol-Myers Squibb (BMY) Financials

$50.00 -1.34 (-2.61%)

As of 03:04 PM Eastern

Annual Income Statements for Bristol-Myers Squibb

This table shows Bristol-Myers Squibb's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	1,565	4,457	1,007	4,920	3,439	-9,015	6,994	6,327	8,025	-8,948
Consolidated Net Income / (Loss)	1,631	4,507	975	4,947	3,460	-8,995	7,014	6,345	8,040	-8,933
Net Income / (Loss) Continuing Operations	1,631	4,507	975	4,947	3,460	-8,995	7,014	6,345	8,040	-8,933
Total Pre-Tax Income	2,077	5,915	5,131	5,968	4,975	-6,871	8,098	7,713	8,440	-8,379
Total Operating Income	1,890	4,467	3,446	5,114	5,913	-9,185	7,378	8,289	7,282	-7,486
Total Gross Profit	12,651	14,458	14,762	16,094	18,067	30,745	35,286	35,207	33,400	20,959
Total Revenue	16,560	19,427	20,776	22,561	26,145	42,518	46,385	46,159	45,006	48,300
Operating Revenue	14,045	19,427	20,776	22,561	26,145	42,518	46,385	46,159	45,006	48,300
Total Cost of Revenue	3,909	4,969	6,014	6,467	8,078	11,773	11,099	10,952	11,606	27,341
Operating Cost of Revenue	3,909	4,969	6,014	6,467	8,078	11,773	11,099	10,952	11,606	27,341
Total Operating Expenses	10,761	9,991	11,316	10,980	12,154	39,930	27,908	26,918	26,118	28,445
Selling, General & Admin Expense	4,841	4,979	4,751	4,551	4,871	7,661	7,690	7,814	7,772	8,414
Research & Development Expense	5,920	5,012	6,468	6,332	6,148	10,048	10,195	9,509	9,299	11,159
Amortization Expense	-	-	97	97	1,135	9,688	10,023	9,595	9,047	8,872
Total Other Income / (Expense), net	187	1,448	1,685	854	-938	2,314	720	-576	1,158	-893
Other Income / (Expense), net	187	1,448	1,685	854	-938	2,314	720	-576	1,158	-893
Income Tax Expense	446	1,408	4,156	1,021	1,515	2,124	1,084	1,368	400	554
Net Income / (Loss) Attributable to Noncontrolling Interest	66	50	-32	27	21	20	20	18	15	15
Basic Earnings per Share	$0.94	$2.67	$0.61	$3.01	$2.02	($3.99)	$3.15	$2.97	$3.88	($4.41)
Weighted Average Basic Shares Outstanding	1.67B	1.67B	1.65B	1.63B	2.26B	2.24B	2.18B	2.10B	2.02B	2.03B
Diluted Earnings per Share	$0.93	$2.65	$0.61	$3.01	$2.01	($3.99)	$3.12	$2.95	$3.86	($4.41)
Weighted Average Diluted Shares Outstanding	1.67B	1.67B	1.65B	1.63B	2.26B	2.24B	2.18B	2.10B	2.02B	2.03B
Weighted Average Basic & Diluted Shares Outstanding	1.67B	1.67B	1.65B	1.63B	2.26B	2.24B	2.18B	2.10B	2.02B	2.03B
Cash Dividends to Common per Share	$1.49	$1.53	$1.57	$1.61	$1.68	$1.84	$2.01	$2.19	$2.31	$2.42

This table shows Bristol-Myers Squibb's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	1,606	2,022	2,262	2,073	1,928	1,762	-11,911	1,680	1,211	72
Consolidated Net Income / (Loss)	1,608	2,025	2,267	2,077	1,934	1,762	-11,908	1,684	1,215	76
Net Income / (Loss) Continuing Operations	1,608	2,025	2,267	2,077	1,934	1,762	-11,908	1,684	1,215	76
Total Pre-Tax Income	2,209	1,859	2,770	1,859	2,137	1,674	-11,516	1,286	1,676	175
Total Operating Income	2,069	1,642	2,357	1,743	1,879	1,303	-11,435	1,559	1,910	480
Total Gross Profit	8,835	8,761	8,696	8,192	8,380	8,132	-4,016	8,802	8,673	7,500
Total Revenue	11,218	11,406	11,337	11,226	10,966	11,477	11,865	12,201	11,892	12,342
Operating Revenue	11,218	11,406	11,337	11,226	10,966	11,477	11,865	12,201	11,892	12,342
Total Cost of Revenue	2,383	2,645	2,641	3,034	2,586	3,345	15,881	3,399	3,219	4,842
Operating Cost of Revenue	2,383	2,645	2,641	3,034	2,586	3,345	15,881	3,399	3,219	4,842
Total Operating Expenses	6,766	7,119	6,339	6,449	6,501	6,829	7,419	7,243	6,763	7,020
Selling, General & Admin Expense	1,930	2,266	1,762	1,934	2,003	2,073	2,367	1,928	1,983	2,136
Research & Development Expense	2,418	2,510	2,321	2,258	2,242	2,478	2,695	2,899	2,374	3,191
Amortization Expense	2,418	2,343	2,256	2,257	2,256	2,278	2,357	2,416	2,406	1,693
Total Other Income / (Expense), net	140	217	413	116	258	371	-81	-273	-234	-305
Other Income / (Expense), net	140	217	413	116	258	371	-81	-273	-234	-305
Income Tax Expense	601	-166	503	-218	203	-88	392	-398	461	99
Net Income / (Loss) Attributable to Noncontrolling Interest	2.00	3.00	5.00	4.00	6.00	-	3.00	4.00	4.00	4.00
Basic Earnings per Share	$0.75	$0.95	$1.08	$0.99	$0.94	$0.87	($5.89)	$0.83	$0.60	$0.05
Weighted Average Basic Shares Outstanding	2.13B	2.10B	2.10B	2.09B	2.03B	2.02B	2.03B	2.03B	2.03B	2.03B
Diluted Earnings per Share	$0.75	$0.95	$1.07	$0.99	$0.93	$0.87	($5.89)	$0.83	$0.60	$0.05
Weighted Average Diluted Shares Outstanding	2.13B	2.10B	2.10B	2.09B	2.03B	2.02B	2.03B	2.03B	2.03B	2.03B
Weighted Average Basic & Diluted Shares Outstanding	2.13B	2.10B	2.10B	2.09B	2.03B	2.02B	2.03B	2.03B	2.03B	2.03B

This table details how cash moves in and out of Bristol-Myers Squibb's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-3,186	1,852	1,132	1,531	5,909	2,153	-657	-4,991	2,194	-1,172
Net Cash From Operating Activities	2,105	3,058	5,275	7,066	8,210	14,052	16,207	13,066	13,860	15,190
Net Cash From Continuing Operating Activities	2,105	3,058	5,275	7,066	8,210	14,052	16,207	13,066	13,860	15,190
Net Income / (Loss) Continuing Operations	1,631	4,507	975	4,947	3,460	-8,995	7,014	6,345	8,040	-8,933
Consolidated Net Income / (Loss)	1,631	4,507	975	4,947	3,460	-8,995	7,014	6,345	8,040	-8,933
Depreciation Expense	376	382	789	637	1,746	10,380	10,686	10,276	9,760	9,600
Non-Cash Adjustments To Reconcile Net Income	935	-644	677	1,034	-1,453	12,454	1,703	1,412	1,262	15,802
Changes in Operating Assets and Liabilities, net	-1,082	-1,356	2,598	262	2,769	213	-3,196	-4,967	-5,202	-1,279
Net Cash From Investing Activities	-1,572	1,480	-66	-2,000	-9,913	-10,859	-538	-1,062	-2,295	-21,352
Net Cash From Continuing Investing Activities	-1,572	1,480	-66	-2,000	-9,913	-10,859	-538	-1,062	-2,295	-21,352
Purchase of Property, Plant & Equipment	-820	-1,215	-1,055	-951	-836	-753	-973	-1,118	-1,209	-1,248
Acquisitions	-1,111	-359	-726	-2,372	-24,777	-13,084	-1,610	-4,286	-1,169	-21,821
Purchase of Investments	-3,143	-3,089	-5,419	-2,305	-3,961	-4,172	-5,478	-3,592	-1,774	-769
Divestitures	708	1,334	736	1,249	15,852	870	748	1,305	909	1,099
Sale and/or Maturity of Investments	2,794	4,809	6,398	2,379	3,809	6,280	6,775	6,629	948	1,387
Net Cash From Financing Activities	-3,624	-2,653	-4,077	-3,535	7,621	-1,151	-16,224	-16,962	-9,416	5,127
Net Cash From Continuing Financing Activities	-3,624	-2,653	-4,077	-3,535	7,621	-1,151	-16,224	-16,962	-9,416	5,127
Repayment of Debt	-2,406	0.00	-1,246	-602	-9,178	-2,475	-5,541	-11,237	-3,999	-5,774
Repurchase of Common Equity	0.00	-231	-2,469	-320	-7,300	-1,546	-6,287	-8,001	-5,155	0.00
Payment of Dividends	-2,477	-2,547	-2,577	-2,613	-2,679	-4,075	-4,396	-4,634	-4,744	-4,863
Issuance of Debt	1,259	125	2,215	0.00	26,778	6,945	0.00	5,926	4,455	15,870
Other Financing Activities, net	-	-	-	-	-	-	-	984	27	-106
Effect of Exchange Rate Changes	-95	-33	-	-	-9.00	111	-102	-33	45	-137

This table details how cash moves in and out of Bristol-Myers Squibb's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-3,003	1,368	-277	-623	-857	3,951	-2,185	-3,038	1,597	2,454
Net Cash From Operating Activities	3,687	3,306	2,970	1,887	4,751	4,252	2,834	2,326	5,591	4,439
Net Cash From Continuing Operating Activities	3,687	3,306	2,970	1,887	4,751	4,252	2,834	2,326	5,591	4,439
Net Income / (Loss) Continuing Operations	1,608	2,025	2,267	2,077	1,934	1,762	-11,908	1,684	1,215	76
Consolidated Net Income / (Loss)	1,608	2,025	2,267	2,077	1,934	1,762	-11,908	1,684	1,215	76
Depreciation Expense	2,588	2,521	2,429	2,432	2,435	2,464	2,532	2,596	2,592	1,880
Non-Cash Adjustments To Reconcile Net Income	-28	-158	182	164	418	498	12,723	748	333	1,998
Changes in Operating Assets and Liabilities, net	-481	-1,082	-1,908	-2,786	-36	-472	-513	-2,702	1,451	485
Net Cash From Investing Activities	-2,081	1,213	-210	-329	-410	-1,346	-19,618	-1,319	-219	-196
Net Cash From Continuing Investing Activities	-2,081	1,213	-210	-329	-410	-1,346	-19,618	-1,319	-219	-196
Purchase of Property, Plant & Equipment	-247	-346	-278	-259	-342	-330	-284	-262	-324	-378
Acquisitions	-3,261	-116	-78	-184	-326	-581	-20,053	-1,373	-348	-47
Purchase of Investments	-274	-26	-200	-355	-502	-717	-274	-84	-40	-371
Divestitures	221	490	227	194	247	241	241	270	255	333
Sale and/or Maturity of Investments	1,480	1,211	119	275	513	41	752	130	238	267
Net Cash From Financing Activities	-4,543	-3,246	-3,050	-2,173	-5,160	967	14,644	-4,023	-3,852	-1,642
Net Cash From Continuing Financing Activities	-4,543	-3,246	-3,050	-2,173	-5,160	967	14,644	-4,023	-3,852	-1,642
Repayment of Debt	-2,857	136	-1,512	-124	-10	-2,353	3,070	-5,787	-2,652	-405
Payment of Dividends	-1,154	-1,145	-1,196	-1,197	-1,191	-1,160	-1,212	-1,217	-1,216	-1,218
Other Financing Activities, net	53	179	-92	53	41	25	-97	-6.00	16	-19
Effect of Exchange Rate Changes	-66	95	13	-8.00	-38	78	-45	-22	77	-147

This table presents Bristol-Myers Squibb's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	31,748	33,707	33,551	34,986	129,944	118,481	109,314	96,820	95,159	92,603
Total Current Assets	10,415	13,704	14,854	17,716	29,354	30,192	33,262	27,273	31,770	29,780
Cash & Equivalents	2,385	4,237	5,421	6,911	12,346	14,546	13,979	9,123	11,464	10,346
Short-Term Investments	1,885	2,113	1,391	1,848	3,047	1,285	2,987	130	816	513
Accounts Receivable	4,299	5,543	6,300	5,747	7,685	8,501	9,369	9,886	10,921	10,747
Inventories, net	1,221	1,241	1,166	1,195	4,293	2,074	2,095	2,339	2,662	2,557
Other Current Assets	625	570	576	2,015	1,983	3,786	4,832	5,795	5,907	5,617
Plant, Property, & Equipment, net	4,412	4,980	5,001	5,027	6,252	5,886	6,049	6,255	6,646	7,136
Total Noncurrent Assets	16,921	15,023	13,696	12,243	94,338	82,403	70,003	63,292	56,743	55,687
Long-Term Investments	4,660	2,719	2,480	1,775	767	433	-	0.00	364	320
Goodwill	6,881	6,875	6,863	6,538	22,488	20,547	20,502	21,149	21,169	21,719
Intangible Assets	1,419	1,385	1,210	1,091	63,969	53,243	42,527	35,859	27,072	23,307
Noncurrent Deferred & Refundable Income Taxes	2,844	2,996	1,610	815	510	1,161	1,439	1,344	2,768	4,236
Other Noncurrent Operating Assets	1,117	1,048	1,533	2,024	6,604	7,019	5,535	4,940	5,370	6,105
Total Liabilities & Shareholders' Equity	31,748	33,707	33,551	34,986	129,944	118,481	109,314	96,820	95,159	92,603
Total Liabilities	17,324	17,360	21,704	20,859	78,246	80,599	73,308	65,702	65,674	76,215
Total Current Liabilities	8,017	8,841	9,563	10,654	18,304	19,080	21,868	21,890	22,262	23,774
Short-Term Debt	139	992	987	1,703	3,346	2,340	4,948	4,264	3,119	2,046
Accounts Payable	1,565	1,664	2,248	1,892	2,445	2,713	2,949	3,040	3,259	3,602
Other Current Liabilities	-	-	-	7,059	12,513	14,027	13,971	14,586	15,884	18,126
Total Noncurrent Liabilities	9,307	8,519	12,141	10,205	59,942	61,519	51,440	43,812	43,412	52,441
Long-Term Debt	6,550	5,716	6,975	5,646	43,387	48,336	39,605	35,056	36,653	47,603
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	19	6,454	5,407	4,501	2,166	338	369
Other Noncurrent Operating Liabilities	1,429	1,283	1,164	4,540	10,101	7,776	7,334	6,590	6,421	4,469
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	14,424	16,347	11,847	14,127	51,698	37,882	36,006	31,118	29,485	16,388
Total Preferred & Common Equity	14,266	16,177	11,741	14,031	51,598	37,822	35,946	31,061	29,430	16,335
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	14,266	16,177	11,741	14,031	51,598	37,822	35,946	31,061	29,430	16,335
Common Stock	1,680	1,946	2,119	2,302	44,001	44,617	44,653	45,457	45,976	46,316
Retained Earnings	31,613	33,513	31,160	34,065	34,474	21,281	23,820	25,503	28,766	14,912
Treasury Stock	-16,559	-16,779	-19,249	-19,574	-25,357	-26,237	-31,259	-38,618	-43,766	-43,655
Accumulated Other Comprehensive Income / (Loss)	-2,468	-2,503	-2,289	-2,762	-1,520	-1,839	-1,268	-1,281	-1,546	-1,238
Other Equity Adjustments	-	-	-	-	0.00	-	-	-	0.00	0.00
Noncontrolling Interest	158	170	106	96	100	60	60	57	55	53

This table presents Bristol-Myers Squibb's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Total Assets	98,196	96,820	94,281	93,489	91,263	95,159	99,031	94,646	93,670	92,603
Total Current Assets	26,796	27,273	27,086	28,074	27,632	31,770	28,669	26,890	28,075	29,780
Cash & Equivalents	7,734	9,123	8,995	8,372	7,514	11,464	9,330	6,293	7,890	10,346
Short-Term Investments	1,293	130	274	358	171	816	340	360	204	513
Accounts Receivable	9,613	9,886	10,054	10,112	10,304	10,921	10,447	11,423	11,026	10,747
Inventories, net	2,074	2,339	2,605	2,364	2,436	2,662	2,985	3,077	3,332	2,557
Other Current Assets	6,082	5,795	5,158	6,868	7,207	5,907	5,567	5,737	5,623	5,617
Plant, Property, & Equipment, net	6,035	6,255	6,279	6,355	6,481	6,646	6,750	6,845	6,903	7,136
Total Noncurrent Assets	65,365	63,292	60,916	59,060	56,825	56,743	63,612	60,911	58,692	55,687
Long-Term Investments	-	0.00	-	-	-	364	367	357	324	320
Goodwill	21,112	21,149	21,162	21,163	21,147	21,169	21,738	21,732	21,751	21,719
Intangible Assets	38,179	35,859	33,569	31,303	28,950	27,072	32,760	29,428	26,964	23,307
Noncurrent Deferred & Refundable Income Taxes	1,329	1,344	1,317	1,572	1,514	2,768	2,723	3,323	3,609	4,236
Other Noncurrent Operating Assets	4,745	4,940	4,868	5,022	5,214	5,370	6,024	6,071	6,044	6,105
Total Liabilities & Shareholders' Equity	98,196	96,820	94,281	93,489	91,263	95,159	99,031	94,646	93,670	92,603
Total Liabilities	65,462	65,702	62,395	61,459	62,201	65,674	82,483	77,577	76,470	76,215
Total Current Liabilities	18,930	21,890	19,085	20,150	23,462	22,262	25,822	23,265	22,638	23,774
Short-Term Debt	2,132	4,264	2,752	3,020	5,467	3,119	6,190	3,531	1,078	2,046
Accounts Payable	2,595	3,040	3,194	3,069	2,813	3,259	3,539	3,751	3,469	3,602
Other Current Liabilities	14,203	14,586	13,139	14,061	15,182	15,884	16,093	15,983	18,091	18,126
Total Noncurrent Liabilities	46,532	43,812	43,310	41,309	38,739	43,412	56,661	54,312	53,832	52,441
Long-Term Debt	36,966	35,056	35,078	34,656	32,137	36,653	49,487	48,858	48,674	47,603
Noncurrent Deferred & Payable Income Tax Liabilities	2,881	2,166	1,568	751	399	338	442	461	430	369
Other Noncurrent Operating Liabilities	6,685	6,590	6,664	5,902	6,203	6,421	6,732	4,993	4,728	4,469
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	32,734	31,118	31,886	32,030	29,062	29,485	16,548	17,069	17,200	16,388
Total Preferred & Common Equity	32,671	31,061	31,824	31,973	28,998	29,430	16,490	17,015	17,142	16,335
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	32,671	31,061	31,824	31,973	28,998	29,430	16,490	17,015	17,142	16,335
Common Stock	45,248	45,457	45,432	45,591	45,141	45,976	45,947	46,058	46,188	46,316
Retained Earnings	24,675	25,503	26,568	27,449	28,218	28,766	15,640	16,103	16,097	14,912
Treasury Stock	-36,411	-38,618	-38,808	-39,680	-43,075	-43,766	-43,697	-43,690	-43,675	-43,655
Accumulated Other Comprehensive Income / (Loss)	-841	-1,281	-1,368	-1,387	-1,286	-1,546	-1,400	-1,456	-1,468	-1,238
Other Equity Adjustments	-	-	-	-	-	0.00	-	-	-	0.00
Noncontrolling Interest	63	57	62	57	64	55	58	54	58	53

This table displays calculated financial ratios and metrics derived from Bristol-Myers Squibb's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.29%	17.31%	6.94%	8.59%	15.89%	62.62%	9.10%	-0.49%	-2.50%	7.32%
EBITDA Growth	-29.35%	139.66%	-4.79%	10.32%	23.83%	-58.27%	435.31%	-4.23%	1.17%	-93.29%
EBIT Growth	-12.77%	184.79%	-13.25%	16.31%	-16.64%	-238.11%	217.86%	-4.75%	9.43%	-199.28%
NOPAT Growth	-32.78%	129.33%	-80.76%	547.38%	-2.99%	-256.35%	199.39%	6.70%	1.73%	-175.54%
Net Income Growth	-19.62%	176.33%	-78.37%	407.38%	-30.06%	-359.97%	177.98%	-9.54%	26.71%	-211.11%
EPS Growth	-22.50%	184.95%	-76.98%	393.44%	-33.22%	-298.51%	178.20%	-5.45%	30.85%	-214.25%
Operating Cash Flow Growth	-33.13%	45.27%	72.50%	33.95%	16.19%	71.16%	15.34%	-19.38%	6.08%	9.60%
Free Cash Flow Firm Growth	-77.27%	74.34%	157.63%	-7.51%	-1,862.32%	105.28%	325.41%	-38.86%	24.73%	-130.28%
Invested Capital Growth	4.87%	14.80%	-24.80%	4.04%	651.88%	-12.13%	-12.04%	-3.79%	-7.47%	-3.10%
Revenue Q/Q Growth	0.18%	5.18%	1.00%	2.38%	8.16%	7.93%	2.02%	-1.24%	0.16%	1.82%
EBITDA Q/Q Growth	-28.49%	30.78%	-4.23%	12.14%	-6.72%	-71.74%	184.95%	-0.28%	-1.31%	-63.04%
EBIT Q/Q Growth	-14.42%	33.85%	-7.03%	15.64%	-24.72%	-299.10%	292.58%	0.09%	-2.14%	-21.79%
NOPAT Q/Q Growth	-28.02%	23.88%	-77.20%	269.00%	-30.79%	-21,598.68%	227.79%	-11.63%	-5.45%	-12.35%
Net Income Q/Q Growth	-11.65%	31.75%	-76.80%	238.84%	-39.06%	-32,025.00%	230.25%	-5.19%	-3.17%	-23.26%
EPS Q/Q Growth	-12.26%	32.50%	-75.98%	234.44%	-41.74%	-1,275.86%	231.09%	-3.91%	-2.03%	-22.84%
Operating Cash Flow Q/Q Growth	17.40%	22.37%	-5.82%	52.68%	-14.34%	9.12%	4.53%	-5.44%	7.33%	1.25%
Free Cash Flow Firm Q/Q Growth	6.51%	-14.79%	29.89%	44.05%	-854.76%	105.52%	582.50%	-17.82%	0.20%	23.27%
Invested Capital Q/Q Growth	-7.30%	-0.19%	-23.28%	-10.38%	789.80%	-1.68%	-4.11%	-2.58%	-3.48%	-6.28%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	76.39%	74.42%	71.05%	71.34%	69.10%	72.31%	76.07%	76.27%	74.21%	43.39%
EBITDA Margin	16.29%	33.28%	29.63%	30.10%	32.16%	8.25%	40.50%	38.97%	40.44%	2.53%
Operating Margin	11.41%	22.99%	16.59%	22.67%	22.62%	-21.60%	15.91%	17.96%	16.18%	-15.50%
EBIT Margin	12.54%	30.45%	24.70%	26.45%	19.03%	-16.16%	17.46%	16.71%	18.75%	-17.35%
Profit (Net Income) Margin	9.85%	23.20%	4.69%	21.93%	13.23%	-21.16%	15.12%	13.75%	17.86%	-18.49%
Tax Burden Percent	78.53%	76.20%	19.00%	82.89%	69.55%	130.91%	86.61%	82.26%	95.26%	106.61%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	21.47%	23.80%	81.00%	17.11%	30.45%	0.00%	13.39%	17.74%	4.74%	0.00%
Return on Invested Capital (ROIC)	12.47%	26.01%	5.34%	39.51%	8.82%	-8.32%	9.41%	10.93%	11.78%	-9.40%
ROIC Less NNEP Spread (ROIC-NNEP)	7.23%	-21.94%	-12.00%	8.15%	4.06%	-16.22%	11.42%	9.29%	15.64%	-20.66%
Return on Net Nonoperating Assets (RNNOA)	-1.38%	3.28%	1.57%	-1.42%	1.69%	-11.76%	9.58%	7.98%	14.76%	-29.54%
Return on Equity (ROE)	11.09%	29.29%	6.92%	38.09%	10.51%	-20.08%	18.99%	18.91%	26.53%	-38.95%
Cash Return on Invested Capital (CROIC)	7.72%	12.23%	33.66%	35.55%	-144.22%	4.59%	22.21%	14.79%	19.54%	-6.25%
Operating Return on Assets (OROA)	6.34%	18.07%	15.26%	17.42%	6.03%	-5.53%	7.11%	7.48%	8.79%	-8.93%
Return on Assets (ROA)	4.98%	13.77%	2.90%	14.44%	4.20%	-7.24%	6.16%	6.16%	8.38%	-9.52%
Return on Common Equity (ROCE)	10.98%	28.98%	6.85%	37.80%	10.48%	-20.05%	18.95%	18.87%	26.48%	-38.86%
Return on Equity Simple (ROE_SIMPLE)	11.43%	27.86%	8.30%	35.26%	6.71%	-23.78%	19.51%	20.43%	27.32%	-54.69%
Net Operating Profit after Tax (NOPAT)	1,484	3,404	655	4,239	4,112	-6,430	6,390	6,819	6,937	-5,240
NOPAT Margin	8.96%	17.52%	3.15%	18.79%	15.73%	-15.12%	13.78%	14.77%	15.41%	-10.85%
Net Nonoperating Expense Percent (NNEP)	5.24%	47.95%	17.35%	31.36%	4.76%	7.90%	-2.01%	1.64%	-3.86%	11.26%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	9.68%	10.02%	-7.94%
Cost of Revenue to Revenue	23.61%	25.58%	28.95%	28.66%	30.90%	27.69%	23.93%	23.73%	25.79%	56.61%
SG&A Expenses to Revenue	29.23%	25.63%	22.87%	20.17%	18.63%	18.02%	16.58%	16.93%	17.27%	17.42%
R&D to Revenue	35.75%	25.80%	31.13%	28.07%	23.52%	23.63%	21.98%	20.60%	20.66%	23.10%
Operating Expenses to Revenue	64.98%	51.43%	54.47%	48.67%	46.49%	93.91%	60.17%	58.32%	58.03%	58.89%
Earnings before Interest and Taxes (EBIT)	2,077	5,915	5,131	5,968	4,975	-6,871	8,098	7,713	8,440	-8,379
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	2,698	6,466	6,156	6,791	8,409	3,509	18,784	17,989	18,200	1,221
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.30	4.82	7.00	5.09	1.76	3.35	3.56	4.48	3.34	6.95
Price to Tangible Book Value (P/TBV)	15.07	9.84	22.41	11.15	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	5.43	4.01	3.96	3.16	3.48	2.98	2.76	3.01	2.18	2.35
Price to Earnings (P/E)	57.45	17.48	81.62	14.51	26.47	0.00	18.32	21.98	12.25	0.00
Dividend Yield	2.76%	3.26%	3.11%	3.66%	2.94%	3.28%	3.40%	3.30%	4.72%	4.29%
Earnings Yield	1.74%	5.72%	1.23%	6.89%	3.78%	0.00%	5.46%	4.55%	8.16%	0.00%
Enterprise Value to Invested Capital (EV/IC)	7.21	5.41	7.70	6.24	1.48	2.23	2.45	2.77	2.22	2.77
Enterprise Value to Revenue (EV/Rev)	5.30	3.90	3.90	3.03	4.66	3.79	3.36	3.67	2.79	3.15
Enterprise Value to EBITDA (EV/EBITDA)	32.55	11.71	13.15	10.06	14.47	45.95	8.29	9.41	6.89	124.48
Enterprise Value to EBIT (EV/EBIT)	42.29	12.80	15.78	11.45	24.46	0.00	19.24	21.94	14.87	0.00
Enterprise Value to NOPAT (EV/NOPAT)	59.18	22.25	123.65	16.11	29.60	0.00	24.38	24.81	18.09	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	41.72	24.76	15.35	9.67	14.82	11.48	9.61	12.95	9.05	10.01
Enterprise Value to Free Cash Flow (EV/FCFF)	95.66	47.31	19.63	17.91	0.00	45.46	10.32	18.34	10.90	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.46	0.41	0.67	0.52	0.90	1.34	1.24	1.26	1.35	3.03
Long-Term Debt to Equity	0.45	0.35	0.59	0.40	0.84	1.28	1.10	1.13	1.24	2.90
Financial Leverage	-0.19	-0.15	-0.13	-0.17	0.42	0.73	0.84	0.86	0.94	1.43
Leverage Ratio	2.23	2.13	2.39	2.64	2.51	2.77	3.08	3.07	3.17	4.09
Compound Leverage Factor	2.23	2.13	2.39	2.64	2.51	2.77	3.08	3.07	3.17	4.09
Debt to Total Capital	31.68%	29.10%	40.19%	34.22%	47.48%	57.22%	55.30%	55.82%	57.43%	75.18%
Short-Term Debt to Total Capital	0.66%	4.30%	4.98%	7.93%	3.40%	2.64%	6.14%	6.05%	4.50%	3.10%
Long-Term Debt to Total Capital	31.02%	24.79%	35.21%	26.29%	44.08%	54.58%	49.16%	49.77%	52.92%	72.09%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.75%	0.74%	0.54%	0.45%	0.10%	0.07%	0.07%	0.08%	0.08%	0.08%
Common Equity to Total Capital	67.57%	70.17%	59.27%	65.33%	52.42%	42.71%	44.62%	44.10%	42.49%	24.74%
Debt to EBITDA	2.48	1.04	1.29	1.08	5.56	14.44	2.37	2.19	2.19	40.66
Net Debt to EBITDA	-0.83	-0.37	-0.22	-0.47	3.64	9.81	1.47	1.67	1.49	31.51
Long-Term Debt to EBITDA	2.43	0.88	1.13	0.83	5.16	13.77	2.11	1.95	2.01	38.99
Debt to NOPAT	4.51	1.97	12.16	1.73	11.36	-7.88	6.97	5.77	5.73	-9.47
Net Debt to NOPAT	-1.51	-0.69	-2.03	-0.75	7.43	-5.35	4.32	4.41	3.91	-7.34
Long-Term Debt to NOPAT	4.41	1.68	10.65	1.33	10.55	-7.52	6.20	5.14	5.28	-9.08
Altman Z-Score	5.34	5.41	4.89	4.87	1.50	1.48	2.15	2.45	2.21	1.42
Noncontrolling Interest Sharing Ratio	0.98%	1.07%	0.98%	0.78%	0.30%	0.18%	0.16%	0.17%	0.18%	0.24%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.30	1.55	1.55	1.66	1.60	1.58	1.52	1.25	1.43	1.25
Quick Ratio	1.07	1.35	1.37	1.36	1.26	1.28	1.20	0.87	1.04	0.91
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	918	1,601	4,124	3,814	-67,217	3,548	15,091	9,227	11,509	-3,485
Operating Cash Flow to CapEx	256.71%	251.69%	500.00%	743.01%	982.06%	1,866.14%	1,665.67%	1,168.69%	1,146.40%	1,217.15%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.51	0.59	0.62	0.66	0.32	0.34	0.41	0.45	0.47	0.51
Accounts Receivable Turnover	4.31	3.95	3.51	3.75	3.89	5.25	5.19	4.79	4.33	4.46
Inventory Turnover	2.81	4.04	5.00	5.48	2.94	3.70	5.32	4.94	4.64	10.48
Fixed Asset Turnover	3.75	4.14	4.16	4.50	4.64	7.01	7.77	7.50	6.98	7.01
Accounts Payable Turnover	1.93	3.08	3.07	3.12	3.73	4.56	3.92	3.66	3.69	7.97
Days Sales Outstanding (DSO)	84.74	92.46	104.03	97.45	93.76	69.48	70.31	76.13	84.37	81.87
Days Inventory Outstanding (DIO)	129.84	90.42	73.04	66.63	123.99	98.70	68.55	73.89	78.64	34.84
Days Payable Outstanding (DPO)	189.18	118.59	118.71	116.83	97.98	79.96	93.10	99.80	99.05	45.80
Cash Conversion Cycle (CCC)	25.40	64.29	58.36	47.25	119.76	88.22	45.76	50.22	63.96	70.91
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	12,183	13,986	10,517	10,942	82,271	72,294	63,593	61,185	56,613	54,858
Invested Capital Turnover	1.39	1.48	1.70	2.10	0.56	0.55	0.68	0.74	0.76	0.87
Increase / (Decrease) in Invested Capital	566	1,803	-3,469	425	71,329	-9,977	-8,701	-2,408	-4,572	-1,755
Enterprise Value (EV)	87,831	75,730	80,969	68,308	121,711	161,256	155,767	169,192	125,477	151,984
Market Capitalization	89,914	77,921	82,193	71,397	91,038	126,784	128,120	139,068	98,294	113,461
Book Value per Share	$8.55	$9.68	$7.17	$8.60	$31.67	$16.74	$16.19	$14.61	$14.46	$8.05
Tangible Book Value per Share	$3.58	$4.74	$2.24	$3.92	($21.40)	($15.92)	($12.20)	($12.20)	($9.24)	($14.15)
Total Capital	21,113	23,055	19,809	21,476	98,431	88,558	80,559	70,438	69,257	66,037
Total Debt	6,689	6,708	7,962	7,349	46,733	50,676	44,553	39,320	39,772	49,649
Total Long-Term Debt	6,550	5,716	6,975	5,646	43,387	48,336	39,605	35,056	36,653	47,603
Net Debt	-2,241	-2,361	-1,330	-3,185	30,573	34,412	27,587	30,067	27,128	38,470
Capital Expenditures (CapEx)	820	1,215	1,055	951	836	753	973	1,118	1,209	1,248
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1,733	-495	-534	6.00	-997	-2,379	-624	394	347	-2,807
Debt-free Net Working Capital (DFNWC)	2,537	5,855	6,278	8,765	14,396	13,452	16,342	9,647	12,627	8,052
Net Working Capital (NWC)	2,398	4,863	5,291	7,062	11,050	11,112	11,394	5,383	9,508	6,006
Net Nonoperating Expense (NNE)	-147	-1,103	-320	-708	652	2,566	-624	474	-1,103	3,693
Net Nonoperating Obligations (NNO)	-2,241	-2,361	-1,330	-3,185	30,573	34,412	27,587	30,067	27,128	38,470
Total Depreciation and Amortization (D&A)	621	551	1,025	823	3,434	10,380	10,686	10,276	9,760	9,600
Debt-free, Cash-free Net Working Capital to Revenue	-10.47%	-2.55%	-2.57%	0.03%	-3.81%	-5.60%	-1.35%	0.85%	0.77%	-5.81%
Debt-free Net Working Capital to Revenue	15.32%	30.14%	30.22%	38.85%	55.06%	31.64%	35.23%	20.90%	28.06%	16.67%
Net Working Capital to Revenue	14.48%	25.03%	25.47%	31.30%	42.26%	26.13%	24.56%	11.66%	21.13%	12.43%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.94	$2.67	$0.61	$3.01	$2.02	($3.99)	$3.15	$2.97	$3.88	($4.41)
Adjusted Weighted Average Basic Shares Outstanding	1.67B	1.67B	1.63B	1.63B	2.26B	2.24B	2.18B	2.10B	2.02B	2.03B
Adjusted Diluted Earnings per Share	$0.93	$2.65	$0.61	$3.01	$2.01	($3.99)	$3.12	$2.95	$3.86	($4.41)
Adjusted Weighted Average Diluted Shares Outstanding	1.67B	1.67B	1.63B	1.63B	2.26B	2.24B	2.18B	2.10B	2.02B	2.03B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$2.02	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.67B	1.67B	1.63B	1.63B	2.26B	2.24B	2.18B	2.10B	2.02B	2.03B
Normalized Net Operating Profit after Tax (NOPAT)	1,484	3,404	2,412	4,239	4,112	-6,430	6,390	6,819	6,937	-5,240
Normalized NOPAT Margin	8.96%	17.52%	11.61%	18.79%	15.73%	-15.12%	13.78%	14.77%	15.41%	-10.85%
Pre Tax Income Margin	12.54%	30.45%	24.70%	26.45%	19.03%	-16.16%	17.46%	16.71%	18.75%	-17.35%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	151.87%	56.51%	264.31%	52.82%	77.43%	-45.30%	62.67%	73.03%	59.01%	-54.44%
Augmented Payout Ratio	151.87%	61.64%	517.54%	59.29%	288.41%	-62.49%	152.31%	199.13%	123.12%	-54.44%

This table displays calculated financial ratios and metrics derived from Bristol-Myers Squibb's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-3.49%	-4.83%	-2.67%	-5.56%	-2.25%	0.62%	4.66%	8.69%	8.44%	7.54%
EBITDA Growth	-1.78%	-1.15%	21.73%	-5.51%	-4.69%	-5.53%	-272.80%	-9.53%	-6.65%	-50.34%
EBIT Growth	2.41%	0.38%	64.20%	-5.06%	-3.26%	-9.95%	-515.74%	-30.82%	-21.57%	-89.55%
NOPAT Growth	19.75%	-37.59%	8.58%	19.01%	12.91%	-23.32%	-514.96%	4.83%	-18.58%	-84.80%
Net Income Growth	3.61%	-14.63%	76.70%	45.35%	20.27%	-12.99%	-625.28%	-18.92%	-37.18%	-95.69%
EPS Growth	8.70%	-11.22%	81.36%	50.00%	24.00%	-8.42%	-650.47%	-16.16%	-35.48%	-94.25%
Operating Cash Flow Growth	-29.98%	-18.51%	-22.09%	-16.54%	28.86%	28.61%	-4.58%	23.26%	17.68%	4.40%
Free Cash Flow Firm Growth	-40.75%	-63.72%	-71.18%	-72.81%	16.57%	41.63%	-411.26%	-76.89%	-74.24%	-66.96%
Invested Capital Growth	-5.30%	-3.79%	-1.95%	-0.84%	-6.61%	-7.47%	2.88%	2.41%	-0.21%	-3.10%
Revenue Q/Q Growth	-5.63%	1.68%	-0.60%	-0.98%	-2.32%	4.66%	3.38%	2.83%	-2.53%	3.78%
EBITDA Q/Q Growth	5.64%	-8.69%	18.70%	-17.46%	6.55%	-9.49%	-317.11%	143.21%	9.94%	-51.85%
EBIT Q/Q Growth	12.82%	-15.84%	49.00%	-32.89%	14.95%	-21.67%	-787.93%	111.17%	30.33%	-89.56%
NOPAT Q/Q Growth	-7.96%	18.76%	7.85%	0.95%	-12.68%	-19.35%	-683.63%	125.50%	-32.18%	-84.95%
Net Income Q/Q Growth	12.53%	25.93%	11.95%	-8.38%	-6.88%	-8.89%	-775.82%	114.14%	-27.85%	-93.74%
EPS Q/Q Growth	13.64%	26.67%	12.63%	-7.48%	-6.06%	-6.45%	-777.01%	114.09%	-27.71%	-91.67%
Operating Cash Flow Q/Q Growth	63.07%	-10.33%	-10.16%	-36.46%	151.78%	-10.50%	-33.35%	-17.93%	140.37%	-20.60%
Free Cash Flow Firm Q/Q Growth	-44.63%	-16.37%	-25.39%	-21.29%	137.36%	1.61%	-263.97%	105.84%	164.56%	30.32%
Invested Capital Q/Q Growth	2.13%	-2.58%	-1.21%	0.88%	-3.80%	-3.48%	9.85%	0.42%	-6.27%	-6.28%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	78.76%	76.81%	76.70%	72.97%	76.42%	70.85%	-33.85%	72.14%	72.93%	60.77%
EBITDA Margin	42.76%	38.40%	45.86%	38.22%	41.69%	36.05%	-75.72%	31.82%	35.89%	16.65%
Operating Margin	18.44%	14.40%	20.79%	15.53%	17.13%	11.35%	-96.38%	12.78%	16.06%	3.89%
EBIT Margin	19.69%	16.30%	24.43%	16.56%	19.49%	14.59%	-97.06%	10.54%	14.09%	1.42%
Profit (Net Income) Margin	14.33%	17.75%	20.00%	18.50%	17.64%	15.35%	-100.36%	13.80%	10.22%	0.62%
Tax Burden Percent	72.79%	108.93%	81.84%	111.73%	90.50%	105.26%	103.40%	130.95%	72.49%	43.43%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	27.21%	-8.93%	18.16%	-11.73%	9.50%	-5.26%	0.00%	-30.95%	27.51%	56.57%
Return on Invested Capital (ROIC)	9.72%	11.60%	12.78%	12.80%	11.47%	9.13%	-50.10%	12.61%	9.43%	1.46%
ROIC Less NNEP Spread (ROIC-NNEP)	10.06%	12.42%	13.93%	13.25%	12.26%	10.50%	-60.62%	11.65%	8.95%	1.06%
Return on Net Nonoperating Assets (RNNOA)	8.50%	10.67%	12.84%	11.83%	11.83%	9.91%	-92.87%	17.63%	13.72%	1.52%
Return on Equity (ROE)	18.21%	22.27%	25.62%	24.63%	23.31%	19.04%	-142.97%	30.24%	23.14%	2.98%
Cash Return on Invested Capital (CROIC)	17.39%	14.79%	13.31%	12.54%	18.91%	19.54%	-10.27%	-9.98%	-7.75%	-6.25%
Operating Return on Assets (OROA)	8.80%	7.30%	11.35%	7.72%	9.24%	6.84%	-45.72%	5.21%	7.23%	0.73%
Return on Assets (ROA)	6.41%	7.95%	9.29%	8.63%	8.37%	7.20%	-47.28%	6.82%	5.24%	0.32%
Return on Common Equity (ROCE)	18.18%	22.23%	25.57%	24.59%	23.26%	19.00%	-142.61%	30.17%	23.08%	2.97%
Return on Equity Simple (ROE_SIMPLE)	20.48%	0.00%	23.03%	24.95%	28.63%	0.00%	-37.20%	-38.37%	-42.28%	0.00%
Net Operating Profit after Tax (NOPAT)	1,506	1,789	1,929	1,947	1,701	1,371	-8,005	2,041	1,385	208
NOPAT Margin	13.43%	15.68%	17.02%	17.35%	15.51%	11.95%	-67.46%	16.73%	11.64%	1.69%
Net Nonoperating Expense Percent (NNEP)	-0.34%	-0.82%	-1.15%	-0.45%	-0.78%	-1.37%	10.52%	0.96%	0.48%	0.40%
Return On Investment Capital (ROIC_SIMPLE)	-	2.54%	-	-	-	1.98%	-	-	-	0.32%
Cost of Revenue to Revenue	21.24%	23.19%	23.30%	27.03%	23.58%	29.15%	133.85%	27.86%	27.07%	39.23%
SG&A Expenses to Revenue	17.20%	19.87%	15.54%	17.23%	18.27%	18.06%	19.95%	15.80%	16.68%	17.31%
R&D to Revenue	21.55%	22.01%	20.47%	20.11%	20.45%	21.59%	22.71%	23.76%	19.96%	25.85%
Operating Expenses to Revenue	60.31%	62.41%	55.91%	57.45%	59.28%	59.50%	62.53%	59.36%	56.87%	56.88%
Earnings before Interest and Taxes (EBIT)	2,209	1,859	2,770	1,859	2,137	1,674	-11,516	1,286	1,676	175
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4,797	4,380	5,199	4,291	4,572	4,138	-8,984	3,882	4,268	2,055
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.40	4.48	4.35	3.97	3.94	3.34	6.61	4.87	6.05	6.95
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.08	3.01	3.02	2.81	2.54	2.18	2.40	1.78	2.19	2.35
Price to Earnings (P/E)	21.54	21.98	18.92	15.93	13.79	12.25	0.00	0.00	0.00	0.00
Dividend Yield	3.13%	3.30%	3.32%	3.68%	4.11%	4.72%	4.31%	5.72%	4.63%	4.29%
Earnings Yield	4.64%	4.55%	5.28%	6.28%	7.25%	8.16%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.77	2.77	2.76	2.56	2.46	2.22	2.49	2.06	2.48	2.77
Enterprise Value to Revenue (EV/Rev)	3.72	3.67	3.64	3.45	3.21	2.79	3.40	2.76	3.06	3.15
Enterprise Value to EBITDA (EV/EBITDA)	9.64	9.41	8.83	8.35	7.82	6.89	38.53	35.58	43.93	124.48
Enterprise Value to EBIT (EV/EBIT)	22.57	21.94	18.98	17.92	16.72	14.87	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	22.54	24.81	24.11	21.76	19.66	18.09	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	12.59	12.95	13.66	13.16	11.17	9.05	11.28	9.06	9.67	10.01
Enterprise Value to Free Cash Flow (EV/FCFF)	15.49	18.34	20.55	20.29	12.56	10.90	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.19	1.26	1.19	1.18	1.29	1.35	3.36	3.07	2.89	3.03
Long-Term Debt to Equity	1.13	1.13	1.10	1.08	1.11	1.24	2.99	2.86	2.83	2.90
Financial Leverage	0.84	0.86	0.92	0.89	0.97	0.94	1.53	1.51	1.53	1.43
Leverage Ratio	2.99	3.07	3.11	3.00	3.07	3.17	3.99	3.83	4.00	4.09
Compound Leverage Factor	2.99	3.07	3.11	3.00	3.07	3.17	3.99	3.83	4.00	4.09
Debt to Total Capital	54.43%	55.82%	54.26%	54.05%	56.41%	57.43%	77.09%	75.43%	74.31%	75.18%
Short-Term Debt to Total Capital	2.97%	6.05%	3.95%	4.33%	8.20%	4.50%	8.57%	5.08%	1.61%	3.10%
Long-Term Debt to Total Capital	51.46%	49.77%	50.32%	49.72%	48.21%	52.92%	68.52%	70.34%	72.70%	72.09%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.09%	0.08%	0.09%	0.08%	0.10%	0.08%	0.08%	0.08%	0.09%	0.08%
Common Equity to Total Capital	45.48%	44.10%	45.65%	45.87%	43.50%	42.49%	22.83%	24.50%	25.60%	24.74%
Debt to EBITDA	2.17	2.19	2.00	2.02	2.04	2.19	13.86	14.52	15.06	40.66
Net Debt to EBITDA	1.67	1.67	1.51	1.55	1.62	1.49	11.36	12.58	12.51	31.51
Long-Term Debt to EBITDA	2.05	1.95	1.85	1.86	1.74	2.01	12.32	13.54	14.73	38.99
Debt to NOPAT	5.07	5.77	5.46	5.26	5.13	5.73	-12.22	-11.18	-10.67	-9.47
Net Debt to NOPAT	3.90	4.41	4.12	4.04	4.08	3.91	-10.02	-9.68	-8.86	-7.34
Long-Term Debt to NOPAT	4.79	5.14	5.07	4.84	4.38	5.28	-10.86	-10.43	-10.44	-9.08
Altman Z-Score	2.32	2.25	2.41	2.30	2.16	1.97	1.13	1.46	1.69	1.72
Noncontrolling Interest Sharing Ratio	0.19%	0.17%	0.20%	0.18%	0.21%	0.18%	0.25%	0.23%	0.26%	0.24%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.42	1.25	1.42	1.39	1.18	1.43	1.11	1.16	1.24	1.25
Quick Ratio	0.98	0.87	1.01	0.94	0.77	1.04	0.78	0.78	0.84	0.91
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	5,018	4,197	3,131	2,464	5,850	5,943	-9,746	569	1,507	1,963
Operating Cash Flow to CapEx	1,492.71%	955.49%	1,068.35%	728.57%	1,389.18%	1,288.48%	997.89%	887.79%	1,725.62%	1,174.34%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.45	0.45	0.46	0.47	0.47	0.47	0.47	0.49	0.51	0.51
Accounts Receivable Turnover	4.96	4.79	4.94	4.72	4.51	4.33	4.44	4.32	4.45	4.46
Inventory Turnover	4.53	4.94	4.58	4.75	4.84	4.64	8.89	9.27	8.96	10.48
Fixed Asset Turnover	7.85	7.50	7.44	7.33	7.18	6.98	6.99	7.05	7.09	7.01
Accounts Payable Turnover	3.63	3.66	3.52	3.60	4.03	3.69	7.38	7.39	8.23	7.97
Days Sales Outstanding (DSO)	73.64	76.13	73.90	77.41	80.89	84.37	82.17	84.50	82.06	81.87
Days Inventory Outstanding (DIO)	80.56	73.89	79.65	76.83	75.47	78.64	41.06	39.39	40.73	34.84
Days Payable Outstanding (DPO)	100.58	99.80	103.83	101.47	90.50	99.05	49.46	49.37	44.36	45.80
Cash Conversion Cycle (CCC)	53.62	50.22	49.73	52.77	65.86	63.96	73.77	74.52	78.43	70.91
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	62,805	61,185	60,447	60,976	58,656	56,613	62,188	62,448	58,534	54,858
Invested Capital Turnover	0.72	0.74	0.75	0.74	0.74	0.76	0.74	0.75	0.81	0.87
Increase / (Decrease) in Invested Capital	-3,512	-2,408	-1,202	-517	-4,149	-4,572	1,741	1,472	-122	-1,755
Enterprise Value (EV)	173,929	169,192	166,961	155,891	144,239	125,477	154,774	128,358	145,128	151,984
Market Capitalization	143,795	139,068	138,338	126,888	114,256	98,294	109,076	82,925	103,736	113,461
Book Value per Share	$15.30	$14.61	$15.16	$15.22	$13.88	$14.46	$8.13	$8.39	$8.46	$8.05
Tangible Book Value per Share	($12.47)	($12.20)	($10.91)	($9.75)	($10.10)	($9.24)	($18.75)	($16.84)	($15.57)	($14.15)
Total Capital	71,832	70,438	69,716	69,706	66,666	69,257	72,225	69,458	66,952	66,037
Total Debt	39,098	39,320	37,830	37,676	37,604	39,772	55,677	52,389	49,752	49,649
Total Long-Term Debt	36,966	35,056	35,078	34,656	32,137	36,653	49,487	48,858	48,674	47,603
Net Debt	30,071	30,067	28,561	28,946	29,919	27,128	45,640	45,379	41,334	38,470
Capital Expenditures (CapEx)	247	346	278	259	342	330	284	262	324	378
Debt-free, Cash-free Net Working Capital (DFCFNWC)	971	394	1,484	2,214	1,952	347	-633	503	-1,579	-2,807
Debt-free Net Working Capital (DFNWC)	9,998	9,647	10,753	10,944	9,637	12,627	9,037	7,156	6,515	8,052
Net Working Capital (NWC)	7,866	5,383	8,001	7,924	4,170	9,508	2,847	3,625	5,437	6,006
Net Nonoperating Expense (NNE)	-102	-236	-338	-130	-233	-391	3,904	357	170	132
Net Nonoperating Obligations (NNO)	30,071	30,067	28,561	28,946	29,594	27,128	45,640	45,379	41,334	38,470
Total Depreciation and Amortization (D&A)	2,588	2,521	2,429	2,432	2,435	2,464	2,532	2,596	2,592	1,880
Debt-free, Cash-free Net Working Capital to Revenue	2.08%	0.85%	3.24%	4.90%	4.34%	0.77%	-1.39%	1.08%	-3.33%	-5.81%
Debt-free Net Working Capital to Revenue	21.39%	20.90%	23.45%	24.22%	21.45%	28.06%	19.85%	15.39%	13.73%	16.67%
Net Working Capital to Revenue	16.83%	11.66%	17.45%	17.54%	9.28%	21.13%	6.25%	7.79%	11.46%	12.43%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.75	$0.95	$1.08	$0.99	$0.94	$0.87	($5.89)	$0.83	$0.60	$0.05
Adjusted Weighted Average Basic Shares Outstanding	2.13B	2.10B	2.10B	2.09B	2.03B	2.02B	2.03B	2.03B	2.03B	2.03B
Adjusted Diluted Earnings per Share	$0.75	$0.95	$1.07	$0.99	$0.93	$0.87	($5.89)	$0.83	$0.60	$0.05
Adjusted Weighted Average Diluted Shares Outstanding	2.13B	2.10B	2.10B	2.09B	2.03B	2.02B	2.03B	2.03B	2.03B	2.03B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	2.13B	2.10B	2.10B	2.09B	2.03B	2.02B	2.03B	2.03B	2.03B	2.03B
Normalized Net Operating Profit after Tax (NOPAT)	1,506	1,149	1,929	1,220	1,701	912	-8,005	1,091	1,385	336
Normalized NOPAT Margin	13.43%	10.08%	17.02%	10.87%	15.51%	7.95%	-67.46%	8.94%	11.64%	2.72%
Pre Tax Income Margin	19.69%	16.30%	24.43%	16.56%	19.49%	14.59%	-97.06%	10.54%	14.09%	1.42%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	68.56%	73.03%	63.38%	58.82%	56.96%	59.01%	-77.59%	-73.22%	-66.30%	-54.44%
Augmented Payout Ratio	193.13%	199.13%	107.74%	110.92%	148.14%	123.12%	-157.54%	-134.50%	-66.30%	-54.44%

Frequently Asked Questions About Bristol-Myers Squibb's Financials

When does Bristol-Myers Squibb's fiscal year end?

According to the most recent income statement we have on file, Bristol-Myers Squibb's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Bristol-Myers Squibb's net income changed over the last 9 years?

Bristol-Myers Squibb's net income appears to be on a downward trend, with a most recent value of -$8.93 billion in 2024, falling from $1.63 billion in 2015. The previous period was $8.04 billion in 2023.

What is Bristol-Myers Squibb's operating income?

Bristol-Myers Squibb's total operating income in 2024 was -$7.49 billion, based on the following breakdown:

Total Gross Profit: $20.96 billion
Total Operating Expenses: $28.45 billion

How has Bristol-Myers Squibb revenue changed over the last 9 years?

Over the last 9 years, Bristol-Myers Squibb's total revenue changed from $16.56 billion in 2015 to $48.30 billion in 2024, a change of 191.7%.

How much debt does Bristol-Myers Squibb have?

Bristol-Myers Squibb's total liabilities were at $76.22 billion at the end of 2024, a 16.1% increase from 2023, and a 339.9% increase since 2015.

How much cash does Bristol-Myers Squibb have?

In the past 9 years, Bristol-Myers Squibb's cash and equivalents has ranged from $2.39 billion in 2015 to $14.55 billion in 2020, and is currently $10.35 billion as of their latest financial filing in 2024.

How has Bristol-Myers Squibb's book value per share changed over the last 9 years?

Over the last 9 years, Bristol-Myers Squibb's book value per share changed from 8.55 in 2015 to 8.05 in 2024, a change of -5.8%.

Remove Ads

Related Companies

This page (NYSE:BMY) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bristol-Myers Squibb (BMY) Financials

Frequently Asked Questions About Bristol-Myers Squibb's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bristol-Myers Squibb (BMY) Financials

Annual Income Statements for Bristol-Myers Squibb

Quarterly Income Statements for Bristol-Myers Squibb

Annual Cash Flow Statements for Bristol-Myers Squibb

Quarterly Cash Flow Statements for Bristol-Myers Squibb

Annual Balance Sheets for Bristol-Myers Squibb

Quarterly Balance Sheets for Bristol-Myers Squibb

Annual Metrics and Ratios for Bristol-Myers Squibb

Quarterly Metrics and Ratios for Bristol-Myers Squibb

Frequently Asked Questions About Bristol-Myers Squibb's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools